Soligenix, Inc. (SNGX) shares surged 260.00 percent to $4.50 after announcing that its Phase 2a proof-of-concept study for SGX945 in Behçet's Disease achieved its primary goal of demonstrating biological efficacy.
The stock opened at $1.9010 and traded between $1.6600 and $3.3599, with volume spiking to 174 million shares, vastly exceeding the average of 919,691 on the Nasdaq. Shares had previously closed at $1.2500. The stock now trades near the upper end of its 52-week range of $1.0900 to $5.4000.
The treatment showed comparable results to apremilast in reducing oral ulcers, despite SGX945 being discontinued at week 4, while apremilast continued through week 8—suggesting sustained therapeutic benefit even post-treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.